Publications by authors named "Benjamin Trinite"

Claim this Profile
U
Under the Radar: Immune Evasion, Pathogenesis and Control of HIV Infection.
Ferran Tarrés-Freixas, Benjamin Trinité, Jorge Carrillo, Julià Blanco

Int J Mol Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracking the soluble biomarkers of MIS-C and their association with clinical parameters and severity.
Tetyana Pidkova, Rosa Maria Pino-Ramirez, Victor Urrea, Marta Vidal, Ruth Aguilar

Pediatr Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters.
Edwards Pradenas, Victor Urrea, Silvia Marfil, Tetyana Pidkova, Carmen Aguilar-Gurrieri

J Transl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.
Carla Martín Pérez, Anna Ramírez-Morros, Alfons Jiménez, Marta Vidal, Edwards Pradenas

Commun Med (Lond)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model.
Anna Pons-Grífols, Ferran Tarrés-Freixas, Mònica Pérez, Eva Riveira-Muñoz, Dàlia Raïch-Regué

mBio· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic.
Luis M Molinos-Albert, Rocío Rubio, Carla Martín-Pérez, Edwards Pradenas, Cèlia Torres

Cell Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later.
Rocío Rubio, Alexei Yavlinsky, Marina Escalera Zamudio, Luis M Molinos-Albert, Carla Martín Pérez

J Infect· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Júlia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Cañete

Vaccine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.
Julià Blanco, Benjamin Trinité, Joan Puig-Barberà

Influenza Other Respir Viruses· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.
María Jesús López Fernández, Silvia Narejos, Antoni Castro, José María Echave-Sustaeta, María José Forner

Vaccines (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein.
Raquel Ortiz, Ana Barajas, Anna Pons-Grífols, Benjamin Trinité, Ferran Tarrés-Freixas

Viruses· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
Benjamin Trinité, Eberhard Durr, Anna Pons-Grífols, Gregory O'Donnell, Carmen Aguilar-Gurrieri

Vaccine· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.
Leire de Campos-Mata, Benjamin Trinité, Andrea Modrego, Sonia Tejedor Vaquero, Edwards Pradenas

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models.
Carla Usai, Erola Ainsua-Enrich, Victor Urrea Gales, Edwards Pradenas, Cristina Lorca-Oró

NPJ Vaccines· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Ana Barajas, Pep Amengual-Rigo, Anna Pons-Grífols, Raquel Ortiz, Oriol Gracia Carmona

J Transl Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
Lorna Leal, Judit Pich, Laura Ferrer, Jocelyn Nava, Ruth Martí-Lluch

NPJ Vaccines· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Júlia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Cañete

Lancet Reg Health Eur· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis of Production and Immunogenicity.
Raquel Ortiz, Ana Barajas, Anna Pons-Grífols, Benjamin Trinité, Ferran Tarrés-Freixas

Int J Mol Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.
Eudald Felip, Edwards Pradenas, Margarita Romeo, Silvia Marfil, Benjamin Trinité

Mol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization.
Edwards Pradenas, Silvia Marfil, Víctor Urrea, Macedonia Trigueros, Tetyana Pidkova

iScience· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses.
Ferran Tarrés-Freixas, Carmen Aguilar-Gurrieri, María Luisa Rodríguez de la Concepción, Victor Urrea, Benjamin Trinité

NPJ Vaccines· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
Antonio Barreiro, Antoni Prenafeta, Gregori Bech-Sabat, Mercè Roca, Eva Perozo Mur

iScience· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2.
Jordana Muñoz-Basagoiti, Fábio Luís Lima Monteiro, Lauren R H Krumpe, Victoria Armario-Najera, Shilpa R Shenoy

Proc Natl Acad Sci U S A· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis